摘要
Cord blood(CB)plays an important role as a medical resource containing hematopoietic stem cells(HSCs)and mature immune cells.Cord blood transplantation(CBT)for hematopoietic disorders offers several advantages,including the ability to initiate treatment early,lower rates of severe chronic graft-versus-host disease even in human leukocyte antigen(HLA)-mismatched recipients,resulting in better post-transplant quality of life,and stronger anti-tumor immune responses compared to other transplantation methods,thereby reducing the risk of post-transplant relapse. In addition,techniques such as the introduction of chimeric antigen receptor genes have been used to enable immune cells in CB,such as T cells and natural killer(NK)cells,to be used as sources for cell therapies.
